Skip to content
  • Brazil
  • Canada
  • Europe
  • India
  • Italy
  • Japan
  • Korea
  • Latam
  • Spain
  • Taiwan
  • The Middle East
  • Turkey
  • United Kingdom
  • United States
  • Country/Region
  • No block ID is set

  • Clinic Portal
    • +0034963905310
  • Request Information
  • +34 96 390 53 10
  • Part of brands: |
InternationalInternational
  • Country/Region
  • Part of brands: |
  • Patient Journey
    • Before Pregnancy
    • IVF Process
    • Healthy pregnancy
    • After birth
  • Reproductive Health
    • Specialists
      • ERA
      • ERA insight Hub
      • ALICE
      • EMMA
      • EndomeTRIO
      • Infertility Panels
      • EMBRACE
      • PGT-A
      • PGT-A Plus
      • PGT-M
      • PGT-SR
      • CGT
      • NACE
      • Zenit
      • POC Portfolio
      • SAT
      • Newborn Screening
  • Diagnostics
  • About us
    • Igenomix Research
    • About Igenomix
    • Igenomix Worldwide
  • Academy
  • Blog
Genomics Precision Diagnostic > Neurology Precision Panel > Hereditary Spastic Paraplegia Precision Panel

Hereditary Spastic Paraplegia Precision Panel

Hereditary Spastic Paraplegia (HSP) includes a group of familial diseases that are characterized by progressive degeneration of the corticospinal tracts responsible for movement and sensation. HSPs are differentiated into “pure” forms if there is bladder involvement and “complicated” if there are additional neurologic or systemic abnormalities.
Overview
Indication
Clinical Utility
Genes & Diseases
Methodology
References

Overview

  • Hereditary Spastic Paraplegia (HSP) includes a group of familial diseases that are characterized by progressive degeneration of the corticospinal tracts responsible for movement and sensation. HSPs are differentiated into “pure” forms if there is bladder involvement and “complicated” if there are additional neurologic or systemic abnormalities. The genetic classification of HSP is based upon the mode of inheritance, chromosomal locus, and causative mutation. Modes of inheritance include autosomal dominant, autosomal recessive and X-linked forms. The correlation of clinical classification with genetic classification is not yet defined as some genetic types of HSP are associated with both pure and complex phenotypes. 

  • The Igenomix Hereditary Spastic Paraplegia Precision Panel  can serve as an accurate and directed diagnostic tool as well as a differential diagnosis of muscle weakness ultimately leading to a better management and prognosis of the disease. It provides a comprehensive analysis of the genes involved in this disease using next-generation sequencing (NGS) to fully understand the spectrum of relevant genes involved. 

Indication

  • The Igenomix Hereditary Spastic Paraplegia Precision Panel is indicated in patients with a clinical suspicion or diagnosis presenting with or without the following manifestations: 

    • Leg weakness 
    • Leg spasticity 
    • Brisk tendon reflexes 
    • Extensor plantar reflex 
    • Bladder dysfunction (urinary urgency) 
    • Visual loss 
    • Hearing loss 
    • Difficulty speaking
    • Peripheral neuropathy 

Clinical Utility

The clinical utility of this panel is: 

  • The genetic and molecular diagnosis for an accurate clinical diagnosis of a symptomatic patient.  
  • Early initiation of treatment with a multidisciplinary team for symptomatic treatment to improve mobility, increase range of motion and relieve discomfort using pharmacologic treatment as well as physical medicine and rehabilitation.
  • Risk assessment and genetic counselling of asymptomatic family members according to the mode of inheritance. 
  • Improvement of delineation of genotype-phenotype correlation.

Genes & Diseases

Methodology

References

See scientific referrals

Novarino, G., Fenstermaker, A., Zaki, M., Hofree, M., Silhavy, J., & Heiberg, A. et al. (2014). Exome Sequencing Links Corticospinal Motor Neuron Disease to Common Neurodegenerative Disorders. Science, 343(6170), 506-511. doi: 10.1126/science.1247363 

Fink, J. (2013). Hereditary spastic paraplegia: clinico-pathologic features and emerging molecular mechanisms. Acta Neuropathologica, 126(3), 307-328. doi: 10.1007/s00401-013-1115-8 

Chase, A. (2014). Exome sequencing sheds light on hereditary spastic paraplegia. Nature Reviews Neurology, 10(3), 124-124. doi: 10.1038/nrneurol.2014.27 

Depienne, C., Stevanin, G., Brice, A., & Durr, A. (2007). Hereditary spastic paraplegias: an update. Current Opinion In Neurology, 20(6), 674-680. doi: 10.1097/wco.0b013e3282f190ba 

Züchner, S. (2007). The genetics of hereditary spastic paraplegia and implications for drug therapy. Expert Opinion On Pharmacotherapy, 8(10), 1433-1439. doi: 10.1517/14656566.8.10.1433 

Orlacchio, A., Kawarai, T., Totaro, A., Errico, A., St George-Hyslop, P., Rugarli, E., & Bernardi, G. (2004). Hereditary Spastic Paraplegia. Archives Of Neurology, 61(6), 849. doi: 10.1001/archneur.61.6.849 

descargar

Detail description

Download

Request Information

WE GUIDE YOU

Fertility
Inherited diseases prevention
Healthy pregnancy

To see the accreditation certificate, associated technical annex and list of accredited tests, click on this link.

OUR SERVICES

Genetic testing solutions
For patients
How to send a sample?
User manual

ABOUT US

About Igenomix
Contact
Quality
Complaints
Work with us
Terms and conditions

FOLLOW IGENOMIX

  + 96 390 53 10
  Write us
  • Brazil
  • Canada
  • Europe
  • India
  • Italy
  • Japan
  • Korea
  • Latam
  • Spain
  • Taiwan
  • The Middle East
  • Turkey
  • United Kingdom
  • United States
Country/Region

[2024] © Igenomix Privacy Page Quality policy Legal note Cookies policy

Request Information


  • Patient Journey
    • Before Pregnancy
    • IVF Process
    • Healthy pregnancy
    • After birth
  • Reproductive Health
    • Specialists
      • ERA
      • ERA insight Hub
      • ALICE
      • EMMA
      • EndomeTRIO
      • Infertility Panels
      • EMBRACE
      • PGT-A
      • PGT-A Plus
      • PGT-M
      • PGT-SR
      • CGT
      • NACE
      • Zenit
      • POC Portfolio
      • SAT
      • Newborn Screening
  • Diagnostics
  • About us
    • Igenomix Research
    • About Igenomix
    • Igenomix Worldwide
  • Academy
  • Blog
  • Country/Region
  • +34 96 390 53 10
  • Clinic Portal
  • Request Information